After adjusting for confounding factors, patients with CSU experience worse health outcomes and quality of life than patients with AD or PsO.

The UP-AA clinical program includes 2 studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.

The majority of patients with skin of color and scalp psoriasis who were treated with guselkumab achieved significant scalp clearance.

The FDA is updating opioid safety labels to support treatment decisions based on the latest evidence to reduce misuse.

President Trump ordered the reinstatement of the Presidential Fitness Test program, which tests children's athletic abilities.

New research suggests that the survival benefits observed with different treatments for advanced melanoma vary according to the site of metastasis.